Home Ad Exchange News Viant Co-Founders Buy Back DSP From Meredith

Viant Co-Founders Buy Back DSP From Meredith

SHARE:

More than a year after Meredith said it would sell off Viant, the ad tech company has found its buyer.

Viant co-founders Tim and Chris Vanderhook said Monday they’ve bought back the 60% stake they sold to Time Inc. in 2016, before Time Inc. itself was acquired by Meredith. They declined to reveal the deal price, though the Vanderhooks sold Viant in 2016 for a reported $87 million.

The co-founders bought back the company because it’s “soundly profitable” and experiencing 50% revenue growth this year, co-founder Chris Vanderhook said. The Vanderhooks said they didn’t take on financing to buy back the company.

Post-acquisition, the 300-person company will continue to focus on being an omnichannel, self-serve DSP focused on measurement. “Clients want to know what they get for their money,” Chris Vanderhook said.

The demand-side platform Adelphic, which Viant bought a year after it sold to Time, remains one of Viant’s most prized assets. Adelphic plugs into Viant’s identity graph and powers its self-serve capabilities.

Though it originated as a mobile DSP, Adelphic can now purchase digital out-of-home, video and standard display, enabling marketers to consolidate their spend on the buying platform.

The DSP business has been highly volatile. On one side, there have been numerous strategic acquisitions. Roku bought dataxu. AT&T bought AppNexus. But some platforms have closed up shop. Dstillery shut down its DSP and moved to The Trade Desk.

But the Vanderhooks are confident that being an independent DSP is a good business.

“If you’re successful in building a self-serve, omnichannel DSP, it’s a great business. If you’re pigeonholed or a specialist DSP, your options are limited,” Chris Vanderhook said.

For now, Viant will continue with its data partnership with Meredith, which brought its audience data into the DSP to make it addressable as part of a multi-year agreement. But now that Viant is independent, other publishers could set up similar connections to marry their registration data with Viant’s interest data from its identity graph.

Meredith has slowly been selling Time Inc.-owned assets. Besides Viant, it has also sold Time Inc.’s publications, including Time, Sports Illustrated, Fortune and Money, since Meredith’s strategy centers on female-focused media brands.

Must Read

Rest In Privacy, Sandbox

Last week, after nearly six years of development and delays, Google officially retired its Privacy Sandbox.
Which means it’s time for a memorial service.

AWS Launches A Cloud Infrastructure Service For Ad Tech

AWS RTB Fabric offers ad tech platforms more streamlined integrations with ecosystem and infrastructure partners, allegedly lower latency compared to the public internet and discounts on data transfers.

Netflix Boasts Its Best Ad Sales Quarter Ever (Again)

In a livestreamed presentation to investors on Tuesday, co-CEO Greg Peters shared that Netflix had its “best ad sales quarter ever” in Q3, and more than doubled its upfront commitments for this year.

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters
Comic: No One To Play With

Google Pulls The Plug On Topics, PAAPI And Other Major Privacy Sandbox APIs (As The CMA Says ‘Cheerio’)

Google’s aborted cookie crackdown ends with a quiet CMA sign-off and a sweeping phaseout of Privacy Sandbox technologies, from the Topics API to PAAPI.

The Trade Desk’s Auction Evolutions Bring High Drama To The Prebid Summit

TTD shared new details about OpenAds features that let publishers see for themselves whether it’s running a fair auction. But tension between TTD and Prebid hung over the event.

Monopoly Man looks on at the DOJ vs. Google ad tech antitrust trial (comic).

How Google Stands In The DOJ’s Ad Tech Antitrust Suit, According To Those Who Tracked The Trial

The remedies phase of the Google antitrust trial concluded last week. And after 11 days in the courtroom, there is a clearer sense of where Judge Leonie Brinkema is focused on, and how that might influence what remedies she put in place.